Finvest
WST Healthcare Supplies · Healthcare · Injectables · B2B · Thesis updated July 19, 2026

Injectable drug picks, priced for quality

01 Running thesis

Back to growth, with a price check

West looks stronger than it did during the 2024 and early 2025 destocking period. Customers had been working down extra inventory, which hurt orders and factory use. Q1 2026 makes that look more like a cycle than a broken business.

The clearest signal is guidance. Management raised full-year 2026 organic revenue growth guidance to 7% to 9%, after broad strength in biologics and high-value delivery devices. Proprietary Products also expanded gross margin by 2.0 percentage points year over year to 39.3% in Q1 2026.

The bull case is that West sits inside the approval path for injectable drugs. Once a drug is approved with West components, switching suppliers can be slow, expensive, and risky. Demand from biologics, GLP-1 injections, and stricter sterile packaging rules can support years of growth.

The bear case is not gone. A CEO change is coming in the second half of 2026. The stock already prices in a lot of quality. Customer concentration is rising, and the Daikyo license renewal in 2027 remains a major open item.

Apr 2026▲West raised 2026 organic revenue growth guidance to 7% to 9% after a strong Q1. Proprietary Products organic sales grew 17.5%, and management said a new CEO should be named in the second half of 2026.
Feb 2026→The 2025 10-K showed better Proprietary Products margins, but also more customer concentration. One customer reached 15.8% of sales, and the filing added risk language around alternative drug delivery systems such as oral GLP-1s.
Oct 2025→Q3 2025 growth cooled from the Q2 pace, with Proprietary Products organic sales up 5.1%. Margins still improved, keeping the recovery case alive but less simple.
Jul 2025▲Q2 2025 showed that customer destocking was easing. Proprietary Products organic sales grew 8.4%, and gross margin expanded by 3.1 percentage points.
Apr 2025▲Q1 2025 confirmed the first step out of the destocking cycle. Proprietary Products returned to 2.4% organic sales growth, with a small margin improvement.
Feb 2025▼The 2024 10-K showed the destocking hit was deeper than expected. It also disclosed that the Daikyo license for important technologies expires in 2027.
Oct 2024▲Q3 2024 showed the Proprietary Products sales decline had nearly stopped. Margins were still under pressure, so the key question shifted from demand to margin recovery.
02 Business model

Tiny parts, high switching costs

West sells to drug companies, not patients. Its products include stoppers, seals, containment systems, transfer systems, and self-injection device platforms. These parts help keep injectable drugs stable, clean, and usable.

The business is sticky because West often gets built into a drug's regulatory file. A customer cannot easily swap a stopper or delivery component after approval without testing, paperwork, and risk. That makes quality and trust a real moat.

Most profit power comes from Proprietary Products, where West sells branded high-value components such as Westar, NovaPure, FluroTec, and Daikyo-related technologies. West Vantage adds device design, manufacturing, assembly, and drug handling work.

Where it can break is demand timing and mix. If customers over-order and later cut inventory, West's factories absorb less cost and margins fall. If future drugs move away from injections, some of West's core products could become less needed.

03 Product portfolio

What West actually sells

Cash cow

High-value containment components

Westar, NovaPure, FluroTec, and related components help seal and protect injectable drugs. These are core Proprietary Products and drove the Q1 2026 rebound.

Steady

Daikyo technologies

Daikyo Crystal Zenith and other licensed technologies are part of West's premium offering. The 2027 license renewal is important because these products support the moat.

Growth engine

Self-injection platforms

These help patients take drugs such as obesity and diabetes treatments outside a clinic. Demand for GLP-1 injections is a major growth driver.

Steady

Reconstitution and transfer systems

These systems help prepare and move medicines before use. They fit West's broader role as a supplier of safe drug handling tools.

Growth engine

West Vantage device manufacturing

West Vantage designs, manufactures, and assembles complex devices for pharma, diagnostic, and medical device customers. Q1 2026 organic sales grew 6.2% year over year.

Option

Analytical lab and integrated services

These services help customers test and qualify drug packaging and delivery systems. They can deepen relationships and make West harder to replace.

Option

SmartDose

West expects to close the SmartDose transaction around midyear 2026. After that, this will be less central to the company story.

04 Business segments

Mostly proprietary products

Proprietary Products82%growing fast
West Vantage18%modest

Segment mix is based on Q1 2026 reported net sales, calculated from the 10-Q segment growth disclosures. The top ten customers were 47.6% of 2025 sales, so the mix still has customer concentration risk.

05 Risk factors

What could go wrong

Daikyo license does not renew cleanly

High impact · Medium odds

West licenses key products and processes from Daikyo, including Crystal Zenith and FluroTec-related technology. The agreement expires in 2027. A bad renewal, higher cost, or loss of rights could hurt the premium product set.

We watchManagement comments on Daikyo renewal terms, cost, exclusivity, and product access before the 2027 expiration.

One large customer pulls back

High impact · Medium odds

West's top ten customers were 47.6% of 2025 sales. One customer accounted for 15.8% of sales, up from 12.3% in 2024. That raises the risk that one customer's inventory plans or drug demand can move results.

We watchChanges in top customer concentration, order timing, and any comments about large GLP-1 or biologics programs.

CEO transition changes the playbook

Medium impact · Medium odds

CEO Eric Green plans to retire, with a successor expected in the second half of 2026. A new CEO could change capital allocation, M&A plans, or the pace of divestitures. Even a good handoff can slow decisions for a short time.

We watchThe new CEO appointment, first public strategy comments, and any change to margin or growth targets.

Injectable drug demand shifts

High impact · Medium odds

West depends on drugs that are injected and need special packaging or delivery systems. The 2025 10-K specifically flags alternative delivery systems, such as oral GLP-1s, as a risk. If fewer major drugs need injections, demand for West components could slow.

We watchClinical and commercial progress of oral GLP-1s and other non-injectable drug formats.

Destocking returns

Medium impact · Medium odds

The recent rebound reduced the fear that customer destocking was a long-term problem. But the same issue can return if customers over-order again. Lower volumes can reduce plant absorption, which means factories spread fixed costs over fewer units.

We watchOrganic growth in Proprietary Products, customer inventory comments, and gross margin movement versus the 39.3% Q1 2026 level.
06 Quick answers

In one breath

What does West Pharmaceutical Services do?

West makes components and systems used to package and deliver injectable drugs. Its customers are drug, biologic, generic, diagnostic, and medical device companies.

Why is West tied to GLP-1 drugs?

Many GLP-1 obesity and diabetes drugs are injected. West sells components and device manufacturing services that can support self-injection systems for those drugs.

What is the main bull case for WST stock?

The bull case is that West is a high-quality supplier built into drug approval and manufacturing systems. Q1 2026 growth and raised guidance suggest the business has moved past the destocking slump.

What should investors watch next?

The biggest near-term items are the new CEO, the SmartDose transaction, Proprietary Products margins, and details on the 2027 Daikyo license renewal.